Hypoxic Environment May Lead to Tumor Resistance

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 1
Volume 5
Issue 1

PALO ALTO, Calif--New research into the nature of malignant cells deep within the interior of solid tumors suggests a possible explanation as to why tumors with large hypoxic areas tend to be aggressive and treatment resistant.

PALO ALTO, Calif--New research into the nature of malignant cellsdeep within the interior of solid tumors suggests a possible explanationas to why tumors with large hypoxic areas tend to be aggressiveand treatment resistant.

The research team, led by Dr. Amato J. Giaccia of Stanford University,studied the central area of tumors where the blood supply is poor,causing hypoxia. Their work in a murine model showed that thehypoxic state stimulates production of the p53 protein, whichcan block cell proliferation or lead to cell self-destruction.

While large numbers of malignant cells in the tumor interior diein this way, some tumor cells in the hypoxic environment acquirea p53 gene mutation that prevents their destruction and allowsthem to survive with little oxygen, giving them a distinct competitiveadvantage in the hypoxic environment over cells that lack thegene defect, Dr. Giaccia says (Nature, January 4, 1996).

Such tumor cells may be resistant to chemotherapy and radiation,since, thanks to the p53 mutation, they are no longer affectedby the treatment-induced DNA damage that stimulates productionof p53, says Dr. Giaccia and his colleagues at Stanford, MIT,the University of Pennsylvania, and Cold Spring Harbor Laboratory.These resistant cells can eventually take over the entire tumor,producing an aggressive malignancy that is resistant from thetime of diagnosis.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content